Teva recalls seizure drug

Teva headquarters

Teva Pharmaceutical ($TEVA) has its hands full trying to finalize its $40.5 billion buyout of Allergan’s ($AGN) generics business, a deal it expects to close this week. But meanwhile business goes on as usual, and that involves a Teva recall of a seizure drug.

The Israel-based drugmaker is recalling 14,370 units of divalproex sodium delayed-release tablets after they failed unspecified specifications, according to the most recent FDA Enforcement Report. The drug is used to treat certain types of epileptic seizures, as well as for bipolar disorder and migraines. The recall, which was initiated in May, was identified last week by the FDA as a class III.

Teva has been working for more than a year to buy Actavis, the generic drug business of Allergan. Since Teva is already the world’s largest generics producer, the deal has received close scrutiny by regulators around the globe. The FTC said last week that it had approved the merger after Teva agreed to sell the rights and assets to 79 pharmaceutical products, which are being acquired by 11 different generic drugmakers.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Allergan’s generics business has had its own recalls to deal with this year. In February it said it was recalling 54 lots, consisting of nearly 600,000 bottles, of its copy of the ADHD drug Adderall.

- access the recall here

Related Articles:
Teva expects Allergan deal close any day, it says while lifting guidance
Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug
Teva retrieves amphetamines over impurity concerns

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.